证券代码：301207 证券简称：华兰疫苗 公告编号：2025-041 1、股东会届次：2025年第二次临时股东会； 2、股东会召集人：公司董事会； 3、会议召开的合法、合规性：本次股东会会议的召开符合有关法律、行政法 规、部门规章、规范性文件和公司章程的规定。 4、会议召开方式：现场投票+网络投票 （1）现场投票：股东本人出席现场会议或者通过授权委托书（附件二）委托他 人出席现场会议； 华兰生物疫苗股份有限公司 关于召开2025年第二次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 华兰生物疫苗股份有限公司（以下简称"公司"）于2025年8月27日召开第二届董 事会第十六次会议，审议通过了《关于召开2025年第二次临时股东会的议案》，决 定于2025年9月22日下午13:30召开公司2025年第二次临时股东会，现将本次股东会 的有关事项通知如下： 一、召开会议的基本情况 （2）网络投票：本次股东会通过深圳证券交易所交易系统和互联网投票系统向 全体股东提供网络形式的投票平台，股权登记日登记在册的公司股东可以在网络投 票时间内通过上述系统行使表 ...

证券代码：301207 证券简称：华兰疫苗 公告编号：2025-037 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 华兰生物疫苗股份有限公司 第二届董事会第十六次会议决议公告 一、董事会会议召开情况 华兰生物疫苗股份有限公司（以下简称"公司"）第二届董事会第十六次会议于 2025年8月18日以电话或电子邮件方式发出通知，于2025年8月27日以通讯表决方式 召开，会议应出席董事9名，实际出席董事9名。会议的召集和召开符合《公司法》 和《公司章程》的有关规定。 二、董事会会议审议情况 1、会议以 9 票同意，0 票反对，0 票弃权的表决结果通过了《2025 年半年度报 告及其摘要》。 公司严格按照《证券法》及《深圳证券交易所创业板股票上市规则》等有关规 定，完成了 2025 年半年度报告的编制工作。公司董事、高级管理人员对该报告签署 了书面确认意见。 该议案已经公司第二届董事会 2025 年第四次审计委员会会议审议通过。公司审 计委员会认为，公司编制的 2025 年半年度报告的程序符合法律、行政法规和中国证 监会的规定，报告内容真实、准确、完整地反映了上市公 ...

华兰生物疫苗股份有限公司 关于2025年中期利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、华兰生物疫苗股份有限公司2025年中期利润分配预案为：以595,000,033股（已 扣除公司回购专用证券账户中的股份6,027,467股）为基数，向全体股东每10股派发 现金红利6元（含税），共计357,000,019.80元；不送红股，不进行资本公积金转增 股本，剩余未分配利润结转以后年度。 若本次利润分配预案披露日至实施该方案的股权登记日期间，如享有利润分配 权的股本总数发生变动，则以实施分配方案时股权登记日的享有利润分配权的股本 总数为基数，按照分配比例不变的原则对分配总额进行调整。 2、公司现金分红方案不涉及《深圳证券交易所创业板股票上市规则》第 9.4 条 相关规定的可能被实施其他风险警示情形。 证券代码：301207 证券简称：华兰疫苗 公告编号：2025-040 一、审议程序 华兰生物疫苗股份有限公司（以下简称"公司"）于 2025 年 8 月 27 日召开了第 二届董事会第十六次会议，审议通过了《关于 2025 年中 ...

华兰生物疫苗股份有限公司 2025 年半年度报告全文 华兰生物疫苗股份有限公司 2025 年半年度报告 二〇二五年八月 1 华兰生物疫苗股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、董事、高级管理人员保证半年度报告内容的真实、准确、 完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法 律责任。 公司负责人安康、主管会计工作负责人路珂及会计机构负责人(会计主管 人员)苏文冬声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 公司已在本报告中详细描述可能存在的相关风险，敬请查阅本报告第三 节管理层讨论与分析中"公司面临的风险和应对措施"章节的相关内容。 公司经本次董事会审议通过的利润分配预案为：以 595,000,033 股为基数， 向全体股东每 10 股派发现金红利 6 元（含税），送红股 0 股（含税），不以公 积金转增股本。 2 | 目录 | | --- | | 第一节 | 重要提示、目录和释义 2 | | --- | --- | | 第二节 | 公司简介和主要财务指标 6 | | 第三节 | 管理层讨论 ...

Investment Rating - The industry investment rating is maintained at "Overweight" [2][9][30] Core Views - The vaccine industry is currently facing performance pressure in 2024 and Q1 2025, with inventory turnover and accounts receivable turnover needing improvement. The industry is still in a bottoming process due to high competition and declining prices for some products. Demand is also affected by consumer fatigue and insufficient market education, leading to a supply-demand imbalance [9][30] - The industry is actively adjusting pipeline layouts, focusing on technological iteration and innovative vaccines, while increasing R&D efforts for multi-valent products. In the long term, product innovation remains the core of competitive strength, with a focus on innovation and international expansion [9][30] Summary by Sections Recent Developments - Six vaccine companies have released their semi-annual reports, with four companies showing positive revenue growth and three companies reporting positive net profit growth attributable to shareholders. The upcoming week will see a concentrated release of semi-annual reports from vaccine companies, warranting attention to their performance [4][10] Market Performance - The vaccine sector saw a 4.41% increase last week, ranking second among the pharmaceutical sub-sectors. Year-to-date, the cumulative increase in the vaccine sector has expanded to 6.79% [5][12] Company Performance - The top-performing companies in the vaccine industry last week included Olin Bio, Wantai Bio, and Kangtai Bio, while the underperformers included Kanghua Bio and Zhifei Bio [6][12] Valuation - The vaccine sector's PE (ttm) was 85.49X, up by 3.67X week-on-week, with a one-year maximum of 85.49X and a minimum of 19.57X. The PB (lf) was 2.09X, also showing a week-on-week increase [7][8] Investment Recommendations - The report emphasizes the importance of focusing on companies with strong R&D capabilities and technological advantages, recommending Kangxino for its innovation strength and Kanghua Bio for its demand stability. Attention is also drawn to the upcoming semi-annual reports and changes in inventory and accounts receivable [10][30]

Core Viewpoint - The company reported a significant increase in revenue but a drastic decline in net profit, indicating challenges in profitability despite higher sales [1][2]. Financial Performance - Revenue for the first half of 2025 reached 1.392 billion yuan, a year-on-year increase of 15.81% - Net profit attributable to shareholders was 37.53 million yuan, down 77.30% year-on-year [1] - Operating costs and R&D expenses were 335 million yuan and 297 million yuan, respectively, reflecting increases of 71.67% and 34.85% [2] Product Performance - Key products include the acellular DTP-Hib combination vaccine, hepatitis B vaccine, PCV13 vaccine, and human rabies vaccine - The batch release numbers for the combination vaccine, PCV13 vaccine, and human rabies vaccine saw significant declines of 84%, 44.31%, and 100% year-on-year, respectively [4][5] Market Trends - The industry is experiencing intense competition, with many players in the market leading to reduced profitability - The trend towards multi-valent vaccines is noted, with the company developing new combination vaccines to meet market demands [5][6] International Expansion - The company is focusing on international markets, with a recent approval for local assembly of the PCV13 vaccine in Indonesia, marking a shift towards localized production [8][10] - Current overseas revenue remains limited, contributing less than 2% to total revenue, highlighting the need for further international growth [10] Accounts Receivable - The company's accounts receivable have significantly increased from 1.46 billion yuan at the end of 2021 to 2.913 billion yuan by mid-2025, representing over 20% of total assets [11]

Macro Strategy - In July, non-bank deposits increased by 2.14 trillion yuan, the highest level for the same period since 2015, indicating a potential shift of funds into the stock market [2][3] - By 2024, the number of data enterprises in China is expected to exceed 400,000, with the data industry scale reaching 5.86 trillion yuan, a 117% increase compared to the end of the 13th Five-Year Plan [2] - The micro-short drama market in China reached a scale of 50.5 billion yuan in 2024, surpassing annual box office revenue for films for the first time [2][3] Innovative Drug Industry - The global biotech sector saw significant gains, with the Hang Seng Biotech Index rising by 6.87%, driven by upcoming events like the World Conference on Lung Cancer [5] - The domestic innovative drug industry is entering a pivotal phase where innovation results are expected to translate into performance, with a focus on the upcoming National Medical Insurance Directory negotiations for 2025 [5][7] - The 2025 World Conference on Lung Cancer will feature key presentations from companies like Kangfang Biotech and Fuhong Hanlin, showcasing their innovative products and clinical trial results [6] Vaccine Industry - The domestic vaccine sector is experiencing a significant shift, with the approval of a new vaccine for clinical trials and the first vaccine product passing the commercial insurance innovation drug directory review [12][13] - The vaccine market saw a 1.3% increase last week, with a cumulative increase of 2.28% in 2025 [14] - The vaccine industry is currently facing challenges due to supply-demand imbalances, but long-term prospects remain positive with a focus on innovation and international expansion [17][19] Electronic Industry - The electronic sector experienced a 7.02% increase last week, with notable gains in semiconductor and consumer electronics segments [20] - Huawei's launch of the UCM technology is expected to enhance domestic computing power demand, optimizing AI inference experiences [23][24] - Investment opportunities are seen in AI infrastructure and supply chains for consumer electronics, with a recommendation to maintain an "overweight" rating for the electronic industry [24] Securities Industry - The securities sector outperformed the market, with the broker index rising by 8.2%, indicating a recovery in valuation levels [26] - Daily trading volume in the stock market exceeded 20 trillion yuan, suggesting a positive trend for brokerage performance in the upcoming quarter [27][28] - The recommendation for the securities industry remains "overweight," with a focus on internet brokers that exhibit strong beta characteristics [29]

Core Viewpoint - On August 18, a total of 19 listed companies had their restricted shares unlocked, with a total market value of approximately 32.581 billion yuan [1]. Group 1: Unlocking Details - The specific details of the restricted share unlocks are as follows: - **Sunshine Energy (000591)**: 314 million shares from A-share original shareholder allocation [2] - **Paislin (600215)**: 2.0375 million shares from equity incentive lock-up [2] - **Xin'ao Co. (600803)**: 253 million shares from A-share corporate allocation [2] - **Hualan Biological (301207)**: 459 million shares with extended lock-up period [2] - **Taihe New Materials (002254)**: 436,000 shares from equity incentive lock-up [2] - **Yinxi Technology (300221)**: 569,890 shares from equity incentive lock-up [2] - **Loxin Medical (300562)**: 110,000 shares from equity incentive lock-up [2] - **Bona Film (001330)**: 319 million shares from pre-issue lock-up [2] - **Yuanfei Pet (001222)**: 112 million shares from pre-issue lock-up [2] - **Kaige Precision Machinery (301338)**: 72.1 million shares from pre-issue lock-up [2] - **Dingjide (603255)**: 72.7914 million shares from pre-issue lock-up [2] - **Shangji Technology (301330)**: 18.515 million shares from pre-issue lock-up [2] - **Zhongchumai (688267)**: 83.3928 million shares [2] - **Luwei Optoelectronics (688401)**: 77.6214 million shares [2] - **Haohan Depth (688292)**: 10.8085 million shares [2] - **Huicheng Co. (688403)**: 259 million shares [2] - **Kaiweite (688693)**: 921,100 shares [2] - **Xinyu Ren (688573)**: 122,190 shares [2] - **Sinan Navigation (688592)**: 77,700 shares [2]

Group 1 - The State Council Information Office will hold a press conference on the development of socialist democracy during the "14th Five-Year Plan" period [2] - The 2025 Global Smart Education Conference will take place in Beijing, focusing on the theme of "Human-Machine Collaboration to Foster a New Education Ecosystem" [3] - A total of 26.26 billion shares from 17 companies will be unlocked today, with a total market value of 46.718 billion yuan [4] Group 2 - Four companies have disclosed stock repurchase progress, with two companies announcing new repurchase plans [5][6] - The highest repurchase amounts reported are 20 million yuan and 193,500 yuan for Honghui New Materials and Small Commodity City, respectively [5] - A total of 1,120 billion yuan in 7-day reverse repos will mature today, with an operation rate of 1.40% [7]

格隆汇8月18日｜Wind数据显示，周一（8月18日），共有17家公司限售股解禁，合计解禁量为26.26亿 股，按最新收盘价计算，合计解禁市值为467.18亿元。从解禁量来看，10家公司解禁股数超千万股。格 科微、华兰疫苗、太阳能解禁量居前，解禁股数分别为10.5亿股、4.59亿股、3.14亿股。从解禁市值来 看，10家公司解禁股数超亿元。格科微、华兰疫苗、珂玛科技解禁市值居前，解禁市值分别为163.91亿 元、85.28亿元、48.8亿元。从解禁股数占总股本比例来看，6家公司解禁比例超10%。华兰疫苗、中触 媒、格科微解禁比例居前，解禁比例分别为76.37%、47.33%、40.38%。 ...